Navigation Links
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Date:11/9/2008

Phase 1 Data Demonstrate Safety and Improvement in Heart Failure in a

Majority of Patients

NEW ORLEANS, Nov. 9 /PRNewswire/ -- Celladon Corporation announced today results from the first nine patients treated with MYDICAR(R), a genetically-targeted enzyme replacement therapy for advanced heart failure, showing the product was safe and demonstrating improvement across a number of key parameters. Phase 1 data from the "Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial" were presented at the American Heart Association Scientific Sessions 2008.

This first phase of the multi-center trial was designed to investigate safety and biological effects of restoring SERCA2a enzyme activity in heart muscle cells. The enzyme levels are decreased in late stages of heart failure, and extensive research shows loss of SERCA2a levels represents a common pathway resulting in a defect in the ability of the heart to contract properly. Replacing the enzyme may restore function and reverse heart failure.

"The CUPID trial is the first to attempt to rescue a failing heart by replacing an enzyme known to play a critical role in normal cardiac muscle cell activity," said Brian E. Jaski, M.D., Medical Director of Advanced Heart Failure, Sharp Memorial Hospital, San Diego Cardiac Center, San Diego, and a principal investigator on the study. "Our objective in this study is not only to improve the symptoms of heart failure, but restore physiologic function and reverse the severity of the disease in this chronic patient population."

Celladon scientists, led by company co-founder Roger J. Hajjar, M.D., Director of the Cardiovascular Research Center at Mount Sinai School of Medicine, New York, developed MYDICAR for restoring the SERCA2a calcium transporter in heart failure and validated the overall beneficial effects on cardiac function. MYDICAR
'/>"/>

SOURCE Celladon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015  The recent flurry of PBM ... employer groups scrambling to identify a pharmacy benefit ... care plan, retail pharmacy chain, or other potentially ... purchase of Catamaran, Rite Aid,s $2 billion acquisition ... Omni-Care for $10 billion are just the latest ...
(Date:5/28/2015)... May 28, 2015 The Federal Trade ... antitrust suit charging Cephalon, Inc. with illegally blocking ... The settlement ensures that Teva Pharmaceutical Industries, Ltd., ... total of $1.2 billion available to compensate purchasers, ... because of Cephalon,s illegal conduct.  ...
(Date:5/28/2015)... , May 28, 2015 Lungpacer Medical, ... catheter-based phrenic-nerve-pacing system announced today that it will ... Conference on Thursday, June 4, 2015 in New ... 11:30 a.m. Eastern Time.   About ... a preclinical stage medical device company pioneering the ...
Breaking Medicine Technology:Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 2FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 3
... Conn., Sept. 23, 2011 Butrans® (Buprenorphine) Transdermal System ... pain over the last 24 hours" scores compared to ... moderate-to-severe chronic low back pain , according to ... online, August issue of The Journal of Pain ...
... 2011 Take Care Health Systems, a wholly-owned subsidiary ... Sanofi US today announced the opening of a full-service ... in Bridgewater, New Jersey. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO) ... dedicated to solving health challenges, it is essential for ...
Cached Medicine Technology:Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 2Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 3Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 4Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 5Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 6Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy 2Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy 3Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy 4Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy 5
(Date:5/28/2015)... Restricting access to firearms for people who ... more clearly define alcohol misuse should be developed to ... and public policies by the UC Davis Violence Prevention ... in the peer-reviewed journal Preventive Medicine , summarizes ... misuse in association with firearm access and use, including ...
(Date:5/28/2015)... 28, 2015 AMVETS leaders this week ... winner Robert Davis of Newark, Del. AMVETS National Commander ... on winning the $10,000 sweepstakes grand prize. , AMVETS ... entries from around the country for prizes ranging from ... place on May 21 at the AMVETS National Headquarters ...
(Date:5/28/2015)... The Paw Project, an international ... intended to educate the Oregon public about the harmful ... of Market Street and Park Avenue in Salem, Oregon's ... De-clawing Cats, Raise Your Hand,” depicts a human hand ... a graphic and anatomically-correct representation of the declaw surgery ...
(Date:5/28/2015)... PA (PRWEB) May 28, 2015 The ... today announced a just launched blog series which provides ... Hosted on the “R. Bruce Dalglish” profile on ... of R. Bruce Dalglish’s corporate experience. , “Throughout ... positive workplace cultures have upon the overall success of ...
(Date:5/28/2015)... Ticket Down is a reputable source of ... Mexico and Argentina in early September. , Two of ... on the pitch at AT&T Stadium in Arlington/Dallas, TX. Mexico ... friendly on Tuesday, September 8th at 9 p.m. The match ... world including some of the most loved players in the ...
Breaking Medicine News(10 mins):Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 2Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 3Health News:UC Davis Research Finds That Restricting Firearms Access for People who Misuse Alcohol May Prevent Violence 4Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 3Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3
... of C.difficile’s genetic code is reported to have been ... will enable faster diagnosis and treatment of the ailment ... to the Jewish General Hospital’s Dasval. The strain has ... in Quebec. The search can now commence for the ...
... Schepens Eye Research Institute (SERI) found that increasing the ... more enjoyable to the visually impaired. // ,The ... electronic device to help millions suffering eye diseases. People ... suffering from macular degeneration, diabetic retinopathy and other causes ...
... the first to visualize a need for laboratories in the Mexican ... Sustainability Laboratory (BNSL), which extends over an area of 4000 square ... security force and deal with terrorism // with the help ... for the lab come from USA, State of New Mexico and ...
... study done by a researcher Yun Zhang at the Rockefeller ... of worms. // ,The research was mainly conducted on ... the soil and feeds on various bacteria (both harmless and ... to individual behaviors. ,The genes responsible for the ...
... Annals of Internal Medicine this week have found that ... verge of kidney failure is useless. //The study conducted ... London, Canada found that a treatment called "plasma exchange" ... ,This means that the money which is currently ...
... Wahangara, 12 year old boy from Indonesia had a tumor ... the tumor made up around 10% of his body weight.// ... at Mount Elizabeth Hospital involving different specialties. ,The ... an endemic problem in Sumba. The 7.87 inches tumor developed ...
Cached Medicine News:Health News:Visually impaired prefer specially enhanced TV 2Health News:Visually impaired prefer specially enhanced TV 3Health News:Worms Learn To Choose Their Diet 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: